%0 Journal Article
%T Establishing cost-effectiveness of genetic targeting of cancer therapies
%A Valesca P Ret¨¨l
%A EJTh Rutgers
%A MA Joore
%A WH van Harten
%J European Journal of Oncology Pharmacy
%D 2011
%I Pharma Publishing & Media Europe
%X The clinical benefit of a new genomic instrument, the 70-gene signature for breast cancer patients, is being evaluated in a randomised clinical trial. The early, controlled implementation process is supported by a Constructive Technology Assessment to help decision-making in an uncertain time of development.
%U http://www.ppme.eu/Publications/EJOP/Journal-information/Previous-issues/EJOP-Vol.5-2011-Issue-1/Feature/Establishing-cost-effectiveness-of-genetic-targeting-of-cancer-therapies